Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Gains from Investment Securities (2023 - 2025)

CG Oncology (CGON) has disclosed Gains from Investment Securities for 3 consecutive years, with $184000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 30.09% year-over-year to $184000.0, compared with a TTM value of $859000.0 through Dec 2025, down 86.93%, and an annual FY2025 reading of $859000.0, down 86.93% over the prior year.
  • Gains from Investment Securities was $184000.0 for Q3 2025 at CG Oncology, up from -$184000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.6 million in Q4 2024 and bottomed at -$184000.0 in Q2 2025.
  • Average Gains from Investment Securities over 3 years is $2.5 million, with a median of $802653.5 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities grew 18.83% in 2024, then crashed 124.65% in 2025.
  • Year by year, Gains from Investment Securities stood at $5.5 million in 2023, then increased by 18.83% to $6.6 million in 2024, then plummeted by 97.2% to $184000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for CGON at $184000.0 in Q3 2025, -$184000.0 in Q2 2025, and $859000.0 in Q1 2025.